VaxGen Completes Merger With diaDexus
Under the terms of merger agreement, diaDexus expects to operate as a wholly-owned subsidiary of VaxGen. VaxGen has issued approximately 19,960,534 shares to certain diaDexus stockholders and officers,
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
A5 Labs said that its patent application describes its new method for producing therapeutic proteins as well as specifically providing details of the production of its product VI-1718.